Zimmer Partners’s Prelude Therapeutics PRLD Stock Holding History

Zimmer Partners’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-40,000	Closed	-$1.21M	–	157
2020 Q3	$1.21M	Buy	+40,000	New	+$1.13M	0.02%	103

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Zimmer Partners's PRLD Position: Q4 2020 in Review

Zimmer Partners sold out of Prelude Therapeutics (PRLD) in Q4 2020, closing a stake of 40,000 shares — an estimated $1.21M sold.

Zimmer Partners first reported a position in PRLD in Q3 2020 and held it in 1 quarter. The position peaked at $1.21M in Q3 2020. 51 funds tracked by Wall St. Rank hold PRLD as of Q4 2020.

Zimmer Partners reported no remaining Prelude Therapeutics position as of Q4 2020 after selling out during the quarter.
Zimmer Partners sold 40,000 Prelude Therapeutics shares in Q4 2020, an estimated $1.21M.
Zimmer Partners first reported a position in Prelude Therapeutics in Q3 2020 and held it in 1 quarter.
Zimmer Partners's Prelude Therapeutics position peaked at $1.21M in Q3 2020.
51 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2020.

Based on Zimmer Partners's 13F filing for Q4 2020, filed 16 Feb 2021.